Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$10.61 USD
-0.13 (-1.21%)
Updated Nov 29, 2023 04:00 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
EDIT 10.61 -0.13(-1.21%)
Will EDIT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EDIT
CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here's Why
Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD
Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock?
Other News for EDIT
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
Editas Medicine, Inc. (EDIT) 6th Annual Evercore ISI HealthCONx Conference (Transcript)
CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big
Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year
Market Today: Tech Giants and Biotech Suffer Amid Market Retreat